Allysta Pharmaceuticals is a private, venture-backed, clinical-stage biopharmaceutical company developing first-in-class therapeutic peptides that target adiponectin signaling. Its lead compound, ALY688, is described as the first adiponectin receptor agonist to enter human testing, with anti-inflammatory, anti-fibrotic, cell-regenerative and metabolic properties. Allysta is advancing ALY688 as an ophthalmic solution for dry eye disease and as an extended/sustained-release formulation for systemic conditions such as NASH/MASH and Duchenne muscular dystrophy.
Kriya Therapeutics is a clinical-stage biopharmaceutical company building one-time, AAV-based gene therapies for prevalent chronic diseases of high unmet need. Founded in 2019 and headquartered in Morrisville, North Carolina with operations in Silicon Valley, Kriya pairs a proprietary, vertically integrated manufacturing and R&D engine with a pipeline spanning ophthalmology, metabolic disease, and neurology. Its bet: gene therapy shouldn't be reserved for the rare few, but engineered and manufactured at the scale and cost needed to reach millions.